US Patent

US11230530 — Human plasma kallikrein inhibitors

Method of Use · Assigned to Biocryst Pharmaceuticals Inc · Expires 2035-03-09 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that inhibit plasma kallikrein and their use in treating and preventing diseases caused by unwanted plasma kallikrein activity.

USPTO Abstract

Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3300 —
U-3300 —

Patent Metadata

Patent number
US11230530
Jurisdiction
US
Classification
Method of Use
Expires
2035-03-09
Drug substance claim
No
Drug product claim
No
Assignee
Biocryst Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.